This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kilgore, K. S. Articles by Bolling, S. F. Search for Related Content PubMed PubMed Citation Articles by Kilgore, K. S. Articles by Bolling, S. F. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Related Collections Contractile function Cardiovascular Pharmacology Animal models of human disease CV surgery: coronary artery disease

(Circulation. 1999;100:II-351.)
© 1999 American Heart Association, Inc.

Myocardial Protection and Vascular Biology

RSR13, a Synthetic Allosteric Modifier of Hemoglobin, Improves Myocardial Recovery Following Hypothermic Cardiopulmonary Bypass

Kenneth S. Kilgore, PhD; Charles F. Shwartz, MD; Marsha A. Gallagher, BS; Robert P. Steffen, PhD; Ralph S. Mosca, MD; Steven F. Bolling, MD

From the Section of Thoracic Surgery, University of Michigan Medical Center, Ann Arbor, Mich, and Allos Therapeutics Inc (R.P.S.), Denver, Colo.

Background—During hypothermic blood cardioplegia, oxygen delivery to myocytes is minimal with ineffective anaerobic metabolism predominating. RSR13, 2-[4-[[(3,5-dimethylanilino) carbonyl]methyl]phenoxy]-2-methylpropionic acid, a synthetic allosteric modifier of hemoglobin (Hb), increases release of oxygen from Hb, increasing oxygen availability to hypoxic tissues, and reverses the hypothermia-dependent increase in Hb oxygen affinity. We studied recovery of myocardial mechanical and metabolic function and examined myocardial morphology after cardioplegia, comparing RSR13 (1.75 mmol/L)-supplemented blood (RSR13-BC) to standard blood cardioplegia (BC).

Methods and Results—Twelve dogs underwent 15 minutes of 37°C global ischemia on cardiopulmonary bypass, followed by 75 minutes of hypothermic cardioplegia (13°C) with either BC (n=6) or RSR13-BC (n=6). There were no differences in baseline function between groups. Cardiac function was assessed after 30 minutes of 37°C reperfusion (BC versus RSR13-BC, respectively) by measuring: % return to normal sinus rhythm (0/100%), % of baseline+dP/dt (33.7±1.7/76.3±1.9), % of baseline-dP/dt (26.6±2.0/81.1±1.6), stroke volume (3.5±0.5/7.1±0.9 mL), cardiac output (340±20/880±40.3 mL/min), and LVEDP (11.3±2.2/0.3±2.9 mm Hg). Postischemic oxidative and metabolic parameters including myocardial lactate, pyruvate, ATP content, and percent water content also were determined. Histological analysis demonstrated preservation of endothelial and myocyte morphology in hearts receiving RSR13-BC compared with BC.

Conclusions—These results indicate that in the setting of hypothermic cardiopulmonary bypass, RSR13 improves recovery of myocardial mechanical and metabolic function compared with standard hypothermic BC. Findings from this study suggest that RSR13-BC, by decreasing hemoglobin oxygen affinity, improves oxidative metabolism and preserves cellular morphology, resulting in significantly improved contractile recovery on reperfusion.

Key Words: cardiopulmonary bypass • hemoglobin • surgery

This article has been cited by other articles:

				O. Eichelbronner, M. D'Almeida, A. Sielenkamper, W. J. Sibbald, and I. H. Chin-Yee Increasing P50 does not improve DO2CRIT or systemic VO2 in severe anemia Am J Physiol Heart Circ Physiol, July 1, 2002; 283(1): H92 - H101. [Abstract] [Full Text] [PDF]